The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation

REFERENCES

• Ahn, J., M. Murphy, S. Kratowicz, A. Wang, A. J. Levine, and D. L. George. 1999. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18:5954–5958.
   PubMed Web of Science ®Google Scholar
• Alarcon, R., C. Koumenis, R. K. Geyer, C. G. Maki, and A. J. Giaccia. 1999. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 59:6046–6051.
   PubMed Web of Science ®Google Scholar
• Ayer, D. E.. 1999. Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol. 9:193–198.
   PubMedGoogle Scholar
• Bartek, J., R. Iggo, J. Gannon, and D. P. Lane. 1990. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893–899.
   PubMed Web of Science ®Google Scholar
• Beer-Romero, P., S. Glass, and M. Rolfe. 1997. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 14:595–602.
   PubMed Web of Science ®Google Scholar
• Bottger, A., V. Bottger, A. Sparks, W. Liu, S. F. Howard, and D. P. Lane. 1997. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860–869.
   PubMed Web of Science ®Google Scholar
• Chehab, N. H., A. Malikzay, E. S. Stavridi, and T. D. Halazonetis. 1999. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. USA 96:13777–13782.
   PubMed Web of Science ®Google Scholar
• Chen, L., S. Agrawal, W. Zhou, R. Zhang, and J. Chen. 1998. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 95:195–200.
   PubMedGoogle Scholar
• Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:2438–2451.
   PubMed Web of Science ®Google Scholar
• Chowdary, D. R., J. J. Dermody, K. K. Jha, and H. L. Ozer. 1994. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14:1997–2003.
   PubMed Web of Science ®Google Scholar
• Damalas, A., A. Ben-Ze'ev, I. Simcha, M. Shtutman, J. Fernando, M. Leal, J. Zhurinsky, B. Geiger, and M. Oren. 1999. Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18:3054–3063.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288–7293.
   PubMed Web of Science ®Google Scholar
• Fuchs, S. Y., V. Adler, T. Buschmann, Z. Yin, X. Wu, S. N. Jones, and Z. Ronai. 1998. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12:2658–2663.
   PubMed Web of Science ®Google Scholar
• Geyer, R. K., Z. K. Yu, and C. G. Maki. 2000. The MDM2 RING finger is required to promote p53 nuclear export. Nat. Cell Biol. 2:569–573.
   PubMed Web of Science ®Google Scholar
• Gottlieb, T. M., and M. Oren. 1996. p53 in growth control and neoplasia. Biochem. Biophys. Acta 1287:77–102.
   PubMed Web of Science ®Google Scholar
• Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. X. Xiao, S. Kumar, P. M. Howley, and D. M. Livingston. 1998. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2:405–415.
   PubMed Web of Science ®Google Scholar
• Gu, J., D. Chen, J. Rosenblum, R. M. Rubin, and Z.-M. Yuan. 2000. Identification of a sequence element from p53 that signals for MDM2-targeted degradation. Mol. Cell. Biol. 20:1243–1253.
   PubMedGoogle Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
   PubMed Web of Science ®Google Scholar
• Hengstermann, A., N. J. Whitaker, D. Zimmer, H. Zentgraf, and M. Scheffner. 1998. Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene 17:2933–2941.
   PubMedGoogle Scholar
• Hofmann, F., F. Martelli, D. M. Livingston, and Z. Wang. 1996. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10:2949–2959.
   PubMed Web of Science ®Google Scholar
• Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27.
   PubMed Web of Science ®Google Scholar
• Honda, R., and H. Yasuda. 1999. Association of p19ARF with MDM2 inhibits ubiquitin ligase activity of MDM2 for tumor suppressor p53. EMBO J. 18:22–27.
   PubMed Web of Science ®Google Scholar
• Hsieh, J., F. S. G. Chan, D. J. O'Connor, S. Mittnacht, S. Zhong, and X. Lu. 1999. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3:181–193.
   PubMed Web of Science ®Google Scholar
• Jiang, Y. H., D. Armstrong, U. Albrecht, C. M. Atkins, J. L. Noebels, G. Eichele, J. D. Sweatt, and A. L. Beaudet. 1998. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21:799–811.
   PubMed Web of Science ®Google Scholar
• Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor protein with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95:8292–8297.
   PubMed Web of Science ®Google Scholar
• Khosravi, R., R. Maya, T. Gottlieb, M. Oren, Y. Shiloh, and D. Shkedy. 1999. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA 96:14973–14977.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–1072.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H., and K. H. Vousden. 1997. Proteolytic cleavage of human p53 by calpain: a potential regulator of p53 stability. Mol. Cell. Biol. 17:460–468.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299–303.
   PubMed Web of Science ®Google Scholar
• Kussie, P. H., S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, and N. P. Pavletich. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948–953.
   PubMed Web of Science ®Google Scholar
• Levine, A. J.. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Maki, C. G., J. M. Huibregtse, and P. M. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:2649–2654.
   PubMed Web of Science ®Google Scholar
• Maki, C. G.. 1999. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J. Biol. Chem. 274:16531–16535.
   PubMedGoogle Scholar
• Mansur, C. P., B. Marcus, S. Dalal, and E. J. Androphy. 1995. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10:457–465.
   PubMedGoogle Scholar
• Murphy, M., A. Hinman, and A. J. Levine. 1996. Wild-type p53 negatively regulates the expression of a microtubule associated protein. Genes Dev. 10:2971–2980.
   PubMed Web of Science ®Google Scholar
• Murphy, M., J. Ahn, K. K. Walker, W. H. Hoffman, R. M. Evans, A. J. Levine, and D. L. George. 1999. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13:2490–2501.
   PubMed Web of Science ®Google Scholar
• Oren, M.. 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274:36031–36034.
   PubMed Web of Science ®Google Scholar
• Prives, C.. 1998. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5–8.
   PubMed Web of Science ®Google Scholar
• Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554–564.
   PubMed Web of Science ®Google Scholar
• Sakamuro, D., P. Sabbatini, E. White, and G. C. Prendergast. 1997. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887–898.
   PubMed Web of Science ®Google Scholar
• Salghetti, S. E., S. Y. Kim, and W. P. Tansey. 1999. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 18:717–726.
   PubMed Web of Science ®Google Scholar
• Sharp, D. A., S. A. Kratowicz, M. J. Sank, and D. L. George. 1999. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274:38189–38196.
   PubMed Web of Science ®Google Scholar
• Shieh, S. Y., Y. Taya, and C. Prives. 1999. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 18:1815–1823.
   PubMed Web of Science ®Google Scholar
• Spataro, V., C. Norbury, and A. L. Harris. 1998. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer 77:448–455.
   PubMed Web of Science ®Google Scholar
• Stommel, J. M., N. D. Marchenko, G. S. Jimenez, U. M. Moll, T. J. Hope, and G. M. Wahl. 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660–1672.
   PubMed Web of Science ®Google Scholar
• Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001–5014.
   PubMed Web of Science ®Google Scholar
• Talis, A. L., J. M. Huibregtse, and P. M. Howley. 1998. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273:6439–6445.
   PubMedGoogle Scholar
• Tao, W., and A. J. Levine. 1999. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96:3077–3080.
   PubMed Web of Science ®Google Scholar
• Venot, C., M. Maratrat, C. Dureuil, E. Conseiller, L. Bracco, and L. Debussche. 1998. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17:4668–4679.
   PubMed Web of Science ®Google Scholar
• Walker, K. K., and A. J. Levine. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93:15335–15340.
   PubMed Web of Science ®Google Scholar
• Waterman, M. J. F., J. L. F. Waterman, and T. D. Halazonetis. 1996. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. Cancer Res. 56:158–163.
   PubMedGoogle Scholar
• Zhang, Y., and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3:579–591.
   PubMed Web of Science ®Google Scholar
• Zhu, J., J. Jiang, W. Zhou, K. Zhu, and X. Chen. 1999. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18:2149–2155.
   PubMedGoogle Scholar